Lucid Diagnostics Inc.

The momentum for this stock is not very good. Lucid Diagnostics Inc. is not a good value stock. Lucid Diagnostics Inc. is a mediocre stock to choose.
Log in to see more information.

News

Ascendiant Capital Markets Lowers Lucid Diagnostics (NASDAQ:LUCD) Price Target to $7.25
Ascendiant Capital Markets Lowers Lucid Diagnostics (NASDAQ:LUCD) Price Target to $7.25

Ticker Report Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) had its target price cut by Ascendiant Capital Markets from $7.50 to $7.25 in a research report issued on Tuesday, Benzinga reports. The firm...\n more…

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

PR Newswire Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress Lucid Diagnostics to Host...\n more…

Lucid Diagnostics partnering with Front Line Mobile Health in esophageal cancer
Lucid Diagnostics partnering with Front Line Mobile Health in esophageal cancer

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

PR Newswire Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health PR Newswire NEW YORK, Sept. 3, 2024...\n more…

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer

PR Newswire Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer Lucid Diagnostics Announces Publication of Analytical...\n more…

Short Interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) Drops By 18.9%
Short Interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) Drops By 18.9%

Ticker Report Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 568,100 shares, a decline...\n more…